Intervention

tanespimycin

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions19

Lead sponsors shown2

Clinical trials

4 shown

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast CancerNCT00096109 · 2005-09-01

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyNCT00118092 · 2005-01-01

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsNCT00058253 · 2003-02-01

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerNCT00004065 · 1999-07-01

Common conditions

Recurrent Prostate Cancer2 Stage IV Prostate Cancer2 Unspecified Adult Solid Tumor, Protocol Specific2 Adenocarcinoma of the Prostate1 Bladder Cancer1 Breast Cancer1 Colorectal Cancer1 Gastric Cancer1 Head and Neck Cancer1 Kidney Cancer1 Leukemia1 Lung Cancer1 Melanoma (Skin)1 Ovarian Cancer1 Prostate Cancer1 Recurrent Breast Cancer1 Stage IIIB Breast Cancer1 Stage IIIC Breast Cancer1 Stage IV Breast Cancer1

Leading sponsors

National Cancer Institute (NCI)3 Memorial Sloan Kettering Cancer Center1

Trial status mix

COMPLETED3

TERMINATED1

Phase mix

PHASE12

PHASE22

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.